Source: PR Newswire
EGF Mapping system aims to improve patient outcomes by enabling precise and personalized ablation strategies
MENLO PARK, Calif., Feb. 1, 2024 /PRNewswire/ — Cortex announced today the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in late October 2023.…
Source: healio.com
Electrographic flow-guided ablation was associated with improvement in freedom from atrial fibrillation at 1 year compared with standard pulmonary vein isolation in patients with nonparoxysmal AF requiring a redo ablation, data showed.
The trial included patients with persistent or long-standing persistent AF who required a redo catheter ablation, Vivek Y.…
Source: PRNewswire
MENLO PARK, Calif., Feb. 3, 2023 /PRNewswire/ — Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation (AF), announced today the 12-month results from the FLOW-AF trial (NCT04473963). The data were presented by Dr. Vivek…
Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor. Ablacon also announced the addition of Dr. David Haines, Professor of Cardiovascular Medicine at Oakland University William Beaumont School of Medicine and Director of the Heart Rhythm Center at Beaumont Health, Royal Oak, MI, to the company’s scientific advisory board (SAB).…
MENLO PARK, Calif., Sept. 10, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark. The new update includes an enhanced physician experience and user interface, along with significantly faster processing times leading to improved procedural efficiency. …
MENLO PARK, Calif., July 23, 2019 /PRNewswire/ — Ablacon Inc. announced today that it has entered into a $10 millionventure debt facility with Western Technology Investment (WTI). The debt is accompanied by a $2 million equity investment in the Company. This financing will help fund Ablacon’s first multicenter randomized clinical trial for Ablamap, an advanced mapping system for patients with atrial fibrillation.…
From powering personalized career sites that recommend open positions that are ideal for a given candidate based on their capabilities as eightfold.ai does today, to scaling the complexity and volume of machine learning algorithms, so they’re more accessible as DataRobot does, machine learning startups are taking on many of business’ most significant challenges.…
MENLO PARK, Calif., April 30, 2019 /PRNewswire/ — Ablacon, Inc., a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib), today announced the closing of a $21.5 million Series A financing round led by Ajax Health. …
